Onconetix Reports Q1 2026 Progress at Proteomedix AG

Onconetix, Inc. provided an update on Q1 2026 progress at its subsidiary, Proteomedix AG, highlighting the performance of Proclarix®, a diagnostic blood test for prostate cancer. The company announced two new peer-reviewed publications that validate Proclarix®’s efficacy in reducing unnecessary biopsies and overdiagnosis of prostate cancer. Additionally, a multi-center PRIME study was initiated in collaboration with Labcorp to validate Proclarix® in the U.S. market. The company also reported its commercial expansion efforts in Europe, particularly in the UK and Turkey.